Allogene Therapeutics Inc (ALLO) — Long-term Investment Intensity
Allogene Therapeutics Inc (ALLO) has a Long-term Investment Intensity of 5.7% as of September 2025. Long-term investments of $24.94 Million represent 5.7% of total assets of $439.77 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See net assets of Allogene Therapeutics Inc for net asset value and shareholders' equity analysis.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Allogene Therapeutics Inc Long-term Investment Intensity (2018–2024)
This chart shows how Allogene Therapeutics Inc's Long-term Investment Intensity has evolved across 7 annual periods from 2018 to 2024. As of September 2025, the intensity stands at 5.7%, reflecting long-term investments of $24.94 Million against total assets of $439.77 Million USD. Also explore Allogene Therapeutics Inc assets under control for the complete picture of this company's asset base.
Annual Long-term Investment Intensity for Allogene Therapeutics Inc (2018–2024)
The table below presents the year-by-year Long-term Investment Intensity for Allogene Therapeutics Inc from 2018 to 2024, covering 7 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see Allogene Therapeutics Inc stock valuation.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2024 | 14.7% | $80.67 Million | $548.71 Million | ▲ +14.1 pp |
| 2023 | 0.6% | $3.65 Million | $642.84 Million | ▼ -8.2 pp |
| 2022 | 8.8% | $71.97 Million | $821.58 Million | ▼ -24.8 pp |
| 2021 | 33.5% | $352.18 Million | $1.05 Billion | ▲ +16.9 pp |
| 2020 | 16.6% | $204.21 Million | $1.23 Billion | ▲ +7.8 pp |
| 2019 | 8.8% | $63.21 Million | $717.80 Million | ▼ -25.0 pp |
| 2018 | 33.9% | $261.97 Million | $773.86 Million | — |